Oryzon Reports 95% Response Rate for Iadademstat Combination in Phase Ib AML Trial

Bitget2026/11/04 14:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oryzon Genomics will present updated iadademstat trial results at the American Society of Hematology meeting in New Orleans, December 12-15, 2026.
Phase Ib ALICE-2 results showed encouraging remissions with manageable safety in newly diagnosed acute myeloid leukemia, supporting planned Phase III development.
The Phase Ib FRIDA combination showed encouraging remissions with manageable safety in heavily pretreated patients with FLT3-mutated, relapsed or refractory leukemia.
Early Phase II results in advanced myeloproliferative neoplasms showed preliminary activity, with no dose-limiting toxicities observed during ongoing dose escalation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oryzon Reports 95% Response Rate for Iadademstat Combination in Phase Ib AML Trial

You may also like

Crypto prices